BIOMAT Database Logo BIOMAT Database Logo

Replacement therapy with a monoclonal antibody purified protein C concentrate in newborns with severe congenital protein C deficiency. 1995

M Dreyfus, and M Masterson, and M David, and G E Rivard, and F M Müller, and W Kreuz, and T Beeg, and A Minford, and J Allgrove, and J D Cohen
Hospital Bicêtre, Paris, France.

Protein C replacement therapy with a monoclonal antibody purified, virus inactivated protein C concentrate was carried out in nine infants (three male, six female) with severe congenital protein C deficiency and life-threatening purpura fulminans and/or thrombosis associated with disseminated intravascular coagulation (DIC). Eight infants were homozygous for protein C deficiency; one was a compound heterozygote. The treatment period varied from 22 days to three years. The half-life of protein C was found to be as short as two to three hours during activation of the coagulation system, increasing to approximately ten hours after stabilization. During the acute phase, protein C levels of 0.10 to 0.25 IU/mL were associated with elevated markers of coagulation activation indicating DIC, while protein C levels greater than 0.25 were associated with normalization of coagulation markers. No product-related side effects were reported. Episodes of bleeding or purpura recurred in all patients who were switched to oral anticoagulant therapy, necessitating reinstatement of protein C replacement therapy, either as needed to control symptoms, or on a long-term prophylactic schedule, alone or in addition to oral anticoagulation. Home treatment with protein C concentrate allowed a near-normal life-style for patients who otherwise would be hospitalized for long periods of time.

UI MeSH Term Description Entries
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D008297 Male Males
D010949 Plasma The residual portion of BLOOD that is left after removal of BLOOD CELLS by CENTRIFUGATION without prior BLOOD COAGULATION. Blood Plasma,Fresh Frozen Plasma,Blood Plasmas,Fresh Frozen Plasmas,Frozen Plasma, Fresh,Frozen Plasmas, Fresh,Plasma, Blood,Plasma, Fresh Frozen,Plasmas,Plasmas, Blood,Plasmas, Fresh Frozen
D011486 Protein C A vitamin-K dependent zymogen present in the blood, which, upon activation by thrombin and thrombomodulin exerts anticoagulant properties by inactivating factors Va and VIIIa at the rate-limiting steps of thrombin formation.
D011693 Purpura Purplish or brownish red discoloration, easily visible through the epidermis, caused by hemorrhage into the tissues. When the size of the discolorization is >2-3 cm it is generally called Ecchymoses (ECCHYMOSIS). Petechiae,Purpuras
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D001766 Blindness The inability to see or the loss or absence of perception of visual stimuli. This condition may be the result of EYE DISEASES; OPTIC NERVE DISEASES; OPTIC CHIASM diseases; or BRAIN DISEASES affecting the VISUAL PATHWAYS or OCCIPITAL LOBE. Amaurosis,Bilateral Blindness,Blindness, Bilateral,Blindness, Legal,Blindness, Monocular,Blindness, Unilateral,Sudden Visual Loss,Unilateral Blindness,Blindness, Acquired,Blindness, Complete,Blindness, Hysterical,Blindness, Transient,Acquired Blindness,Amauroses,Bilateral Blindnesses,Complete Blindness,Hysterical Blindness,Legal Blindness,Monocular Blindness,Sudden Visual Losses,Transient Blindness,Visual Loss, Sudden
D002542 Intracranial Embolism and Thrombosis Embolism or thrombosis involving blood vessels which supply intracranial structures. Emboli may originate from extracranial or intracranial sources. Thrombosis may occur in arterial or venous structures. Brain Embolism and Thrombosis,Cerebral Embolism and Thrombosis,Embolism and Thrombosis, Brain
D003241 Consanguinity The magnitude of INBREEDING in humans. Inbreeding, Human,Consanguineous Marriage,Consanguinous Mating,Consanguineous Marriages,Consanguinities,Consanguinous Matings,Human Inbreeding,Human Inbreedings,Inbreedings, Human,Marriage, Consanguineous,Marriages, Consanguineous,Mating, Consanguinous,Matings, Consanguinous
D004211 Disseminated Intravascular Coagulation A disorder characterized by procoagulant substances entering the general circulation causing a systemic thrombotic process. The activation of the clotting mechanism may arise from any of a number of disorders. A majority of the patients manifest skin lesions, sometimes leading to PURPURA FULMINANS. Consumption Coagulopathy,Coagulation, Disseminated Intravascular,Disseminated Coagulation, Intravascular,Intravascular Coagulation, Disseminated,Intravascular Disseminated Coagulation,Coagulation, Intravascular Disseminated,Coagulations, Disseminated Intravascular,Coagulations, Intravascular Disseminated,Coagulopathies, Consumption,Coagulopathy, Consumption,Consumption Coagulopathies,Disseminated Coagulations, Intravascular,Disseminated Intravascular Coagulations,Intravascular Coagulations, Disseminated,Intravascular Disseminated Coagulations

Related Publications

M Dreyfus, and M Masterson, and M David, and G E Rivard, and F M Müller, and W Kreuz, and T Beeg, and A Minford, and J Allgrove, and J D Cohen
Replacement therapy with a purified protein C concentrate during initiation of oral anticoagulation in severe protein C congenital deficiency.
August 1993, Thrombosis and haemostasis,
M Dreyfus, and M Masterson, and M David, and G E Rivard, and F M Müller, and W Kreuz, and T Beeg, and A Minford, and J Allgrove, and J D Cohen
Long-term management of homozygous protein C deficiency: replacement therapy with subcutaneous purified protein C concentrate.
June 1999, Thrombosis and haemostasis,
M Dreyfus, and M Masterson, and M David, and G E Rivard, and F M Müller, and W Kreuz, and T Beeg, and A Minford, and J Allgrove, and J D Cohen
Treatment of inherited protein C deficiency by replacement therapy with the French purified plasma-derived protein C concentrate (PROTEXEL).
October 2007, Vox sanguinis,
M Dreyfus, and M Masterson, and M David, and G E Rivard, and F M Müller, and W Kreuz, and T Beeg, and A Minford, and J Allgrove, and J D Cohen
Treatment of coumarin-induced skin necrosis with a monoclonal antibody purified protein C concentrate.
June 1993, Archives of dermatology,
M Dreyfus, and M Masterson, and M David, and G E Rivard, and F M Müller, and W Kreuz, and T Beeg, and A Minford, and J Allgrove, and J D Cohen
Purpura fulminans in severe congenital protein C deficiency: monitoring of treatment with protein C concentrate.
January 1996, European journal of pediatrics,
M Dreyfus, and M Masterson, and M David, and G E Rivard, and F M Müller, and W Kreuz, and T Beeg, and A Minford, and J Allgrove, and J D Cohen
Hepatitis C virus transmission by monoclonal antibody purified factor VIII concentrate.
June 1990, Lancet (London, England),
M Dreyfus, and M Masterson, and M David, and G E Rivard, and F M Müller, and W Kreuz, and T Beeg, and A Minford, and J Allgrove, and J D Cohen
Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate.
November 1991, The New England journal of medicine,
M Dreyfus, and M Masterson, and M David, and G E Rivard, and F M Müller, and W Kreuz, and T Beeg, and A Minford, and J Allgrove, and J D Cohen
Replacement therapy for a homozygous protein C deficiency-state using a concentrate of human protein C and S.
December 1988, British journal of haematology,
M Dreyfus, and M Masterson, and M David, and G E Rivard, and F M Müller, and W Kreuz, and T Beeg, and A Minford, and J Allgrove, and J D Cohen
Factor VIII:C inhibitor associated with monoclonal-antibody-purified FVIII concentrate.
August 1990, Lancet (London, England),
M Dreyfus, and M Masterson, and M David, and G E Rivard, and F M Müller, and W Kreuz, and T Beeg, and A Minford, and J Allgrove, and J D Cohen
Factor VIII:C inhibitor associated with monoclonal-antibody purified FVIII concentrate.
June 1990, Lancet (London, England),
Copied contents to your clipboard!